Jun '23. 2021 guideline on radiation exposure after radionuclide therapies: implementation in clinic

home > Uitgaven > Jun '23. 2021 guideline on radiation exposure after radionuclide therapies: implementation in clinic

National guidelines on radionuclide therapies have long been based on a 2005 report (Aanbevelingen ‘Het werken met therapeutische doses radionucliden’), mainly based on iodine-131 ([¹³¹I]NaI) therapies. As new therapies were introduced, mainly lutetium-177 ([¹⁷⁷Lu]Lu) based - with less radiation burden for the environment – and with the implementation of the 2013 basic safety standards directive in European legislation, an update was necessary. In the meantime, dose rate levels for discharge after [¹⁷⁷Lu]Lu were used in the way they were used for [¹³¹I]NaI (20 μSv/h at 1m). Guidelines were revised and implemented by the FMS in 2021, in hopes to reach more uniformity between hospitals as well. We investigated this pursued uniformity by the new guideline and provide insights into its implementation.